Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

墨西哥湾沿岸联盟 (GCC) 研究评估和商业化中心

• 批准号: 10783414
• 负责人: PETER J DAVIES
• 金额: $ 99.94万
• 依托单位: TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-25 至 2027-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10783414
• 关键词: Academic Training; Address; Admission activity; Agreement; Area; Award; Biological Sciences; Biomedical Research; Biomedical Technology; Biotechnology; Businesses; Cancer Center; Clinic; Clinical; Clinical Trials; Collaborations; Complex; Development; Ecosystem; Education; Educational Activities; Educational process of instructing; Eligibility Determination; Employment Opportunities; Ensure; Equilibrium; Evaluation Research; Face; Funding; Goals; Growth; Health; Health Professional; Health Sciences; Healthcare; Hospitals; Incubators; Infrastructure; Institution; Intellectual Property; Investments; Joints; Laboratories; Leadership; Legal; Link; Malignant Neoplasms; Marketing; Medical; Medical center; Medicine; Mentors; Mentorship; Methodist Church; Mission; Outcome; Participant; Patients; Personal Satisfaction; Pharmacologic Substance; Process; Records; Research; Research Institute; Research Personnel; Resources; Rice; Services; Small Business Innovation Research Grant; Small Business Technology Transfer Research; Stream; Talents; Technology; Technology Transfer; Texas; Therapeutic; Time; Training; Training Programs; Translating; Trust; Underrepresented Populations; United States National Institutes of Health; Universities; Work; career networking; catalyst; college; commercialization; design; drug development; drug discovery; education resources; experience; gulf coast; improved; innovation; medical schools; member; novel; programs; research facility; success; technology development; timeline

In recent years, the NIH has awarded over $850M annually to the numerous research institutions and hospitals within the Texas Medical Center (TMC; Houston, TX), producing ever-increasing numbers of biomedical discov- eries. Despite this massive investment, only some of these discoveries advance to the clinic, and even fewer are successfully commercialized to improve patient health and well-being. Texas academic entrepreneurs face significant challenges as they seek to commercialize their discoveries, including a lack of training and resources to support early-stage business and technology development. To address these deficiencies, we will establish the Gulf Coast Consortium Research Evaluation and Commercialization Hub (GCC-REACH) as an inte- grated multi-institutional resource wherein nascent academic entrepreneurs work closely with successful life science experts and experienced biotech executives to develop strategic milestone-driven timelines to rapidly validate the commercial value of their discoveries. GCC-REACH will expand the GCC and TMC infrastructure and resources we have designed to support emerging biomedical companies. Academic entrepreneurs will hail from all GCC-affiliated institutions (Baylor College of Medicine, Texas A&M Health Science Center, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas Southern University, Univer- sity of Houston, the University of Texas Health Science Center, University of Texas Medical Branch), Houston- area colleges and universities with large historically-underrepresented groups, and other Texas research insti- tutions. The GCC-REACH program will provide managerial oversight, access to vetted resources, and seed funds to assist each entrepreneur in progressing to a clear value-added commercialization inflection point. Significance. Discussions with numerous Texas-based researchers, all GCC-affiliated technology transfer of- fices, successful life science companies, and healthcare investors have indicated widespread support for this initiative, noting that it would help launch new companies and advance biomedical discoveries. Importantly, GCC-REACH will pair entrepreneurs who balance full-time clinical, teaching, and laboratory duties with EIRs and expert teams who will provide mentorship and assistance in completing the market analysis, business plans, and technology development strategies. Value proposition. In combination with substantial multi-institutional support, NIH's $4M investment will enable GCC-REACH to train academic entrepreneurs to successfully commercialize novel discoveries. We expect these entrepreneurs will launch approximately 60 highly-competitive early-stage biomedical companies that will be highly competitive for non-dilutive NIH SBIR/STTR funding and venture investment.

近年来，NIH 每年向众多研究机构和医院拨款超过 8.5 亿美元 在德克萨斯医学中心（TMC；德克萨斯州休斯顿）内，产生了越来越多的生物医学发现 系列。尽管投入巨大，但只有部分发现进入临床，甚至更少 已成功商业化，以改善患者的健康和福祉。德克萨斯州学术企业家面临 他们在寻求将其发现商业化时面临重大挑战，包括缺乏培训和资源 支持早期业务和技术开发。为了解决这些缺陷，我们将建立 墨西哥湾沿岸联盟研究评估和商业化中心 (GCC-REACH) 综合的多机构资源，其中新生的学术企业家与成功的生活密切合作 科学专家和经验丰富的生物技术高管制定战略里程碑驱动的时间表，以快速 验证他们的发现的商业价值。 GCC-REACH 将扩展 GCC 和 TMC 基础设施 我们为支持新兴生物医药公司而设计的资源。学术企业家将欢呼 来自所有 GCC 附属机构（贝勒医学院、德克萨斯 A&M 健康科学中心、休斯顿 卫理公会研究所、MD 安德森癌症中心、莱斯大学、德克萨斯南方大学、大学 休斯顿市、德克萨斯大学健康科学中心、德克萨斯大学医学分院），休斯顿 - 拥有大量历史上代表性不足的群体的地区学院和大学，以及其他德克萨斯州的研究机构 学费。 GCC-REACH 计划将提供管理监督、获得经过审查的资源以及种子 资金协助每位创业者走向明确的增值商业化拐点。 意义。与众多德克萨斯州研究人员进行讨论，所有海湾合作委员会附属技术转让- 办公室、成功的生命科学公司和医疗保健投资者都表示对此的广泛支持 倡议，指出这将有助于创办新公司并推进生物医学发现。重要的是， GCC-REACH 将为平衡全职临床、教学和实验室职责的企业家与 EIR 配对 以及专家团队，他们将在完成市场分析、商业计划、 和技术发展战略。 价值主张。结合大量的多机构支持，NIH 的 400 万美元投资将使 GCC-REACH 旨在培训学术企业家成功地将新发现商业化。我们期待这些 企业家将创办约60家具有高度竞争力的早期生物医药公司 在非稀释性 NIH SBIR/STTR 资金和风险投资方面具有高度竞争力。